LB2102

About Legend Biotech

Legend Biotech is a leader in the development of innovative cell therapies, with a primary focus on treating hematologic malignancies and solid tumors. Its landmark achievement is the development and commercialization of CARVYKTI, a BCMA-directed CAR-T therapy approved for relapsed/refractory multiple myeloma, which it co-develops and co-commercializes with Janssen Biotech, Inc. The company leverages its integrated cell therapy platform to build a diversified pipeline, including allogeneic and armored CAR-T candidates, and maintains strategic R&D operations in the U.S., China, and Europe.

About Genscript Biotech

Founded in 2002 and publicly listed on the Hong Kong Stock Exchange, Genscript Biotech has evolved from a pioneering gene synthesis service provider into a fully integrated global biotechnology platform. The company operates through three core segments: Life Science Services and Products, Biologics Contract Development and Manufacturing (CDMO), and its own innovative cell therapy pipeline. Its strategic focus includes leveraging its strong R&D foundation to advance proprietary cell therapies while expanding its global CDMO footprint to capture the booming biologics and cell/gene therapy market.

Therapeutic Areas